{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:44:24Z","timestamp":1791204264788,"version":"4.2.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,4,5]]},"DOI":"10.1001\/jama.2022.2361","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T09:31:01Z","timestamp":1647941461000},"page":"1234","source":"Crossref","is-referenced-by-count":16,"title":["Thromboinflammation and Antithrombotics in COVID-19"],"prefix":"10.1001","volume":"327","author":[{"given":"Jean M.","family":"Connors","sequence":"first","affiliation":[{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Divisions of Cardiovascular Medicine, and Preventive Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"jed220008r1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/jth.v18.6","article-title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.","volume":"18","author":"Cui","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"jed220008r2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.v18.4","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"jed220008r3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"jed220008r4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/jth.v18.7","article-title":"Thromboinflammation and the hypercoagulability of COVID-19.","volume":"18","author":"Connors","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"jed220008r5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood.2020007214","article-title":"Platelet gene expression and function in patients with COVID-19.","volume":"136","author":"Manne","year":"2020","journal-title":"Blood"},{"issue":"10","key":"jed220008r6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome.","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"issue":"10320","key":"jed220008r7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","volume":"399","author":"RECOVERY Collaborative Group","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"jed220008r8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial.","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"jed220008r9","article-title":"Effect of antiplatelet therapy on survival and organ support\u2013free days in critically ill patients with COVID-19: a randomized clinical trial.","author":"REMAP-CAP Writing Committee","journal-title":"JAMA"},{"issue":"17","key":"jed220008r10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial.","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jed220008r11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1055\/a-1485-2372","article-title":"Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial.","volume":"122","author":"Bikdeli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"9","key":"jed220008r12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19.","volume":"385","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"10291","key":"jed220008r13","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"jed220008r14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19.","volume":"385","author":"ATTACC Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"2400","key":"jed220008r15","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial.","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"jed220008r16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial.","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10319","key":"jed220008r17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"key":"jed220008r18","author":"Lown","year":"2013"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2790489\/jama_connors_2022_ed_220008_1648650498.22545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T15:02:23Z","timestamp":1649170943000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2790489"}},"subtitle":["Accumulating Evidence and Current Status"],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":18,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,4,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.2361","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,5]]}}}